HMS174 Competent Cell Set - Novagen

HMS174
F^- recA1 hsdR(rK₁₂^- mK₁₂⁺) (Rif ^R)

HMS174(DE3)
F^- recA1 hsdR(rK₁₂^- mK₁₂⁺) (DE3) (Rif ^R)

HMS174(DE3)pLysS
F^- recA1 hsdR(rK₁₂^- mK₁₂⁺) (DE3) pLysS (Cam^R, Rif ^R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Clickhere for Enduser Declaration (EUD) Form. This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the ′EMD Product′) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com

Toxicity: Multiple Toxicity Values, refer to MSDS

HMS174 strains provide the recA mutation in a K-12 background. Like BLR, these strains may stabilize certain target genes whose products may cause the loss of the DE3 prophage.

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany